Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Albert, RN, Deborah Allen, RN, Thomas A. Waldmann, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142065

Published: 2020

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Kerry Rogers, Anjali Mishra, PhD, Thomas A. Waldmann, MD, Nazli Azimi, PhD PharmD, Paul Frohna, MD PhD PharmD, Anoshie Ratnayake, MD, Thomas P Loughran, Jr., MD, Karen Ballen, MD

Blood (2019) 134 (Supplement_1): 2835.

https://doi.org/10.1182/blood-2019-129291

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Sarah Cooley, MD, Fiona He, MD BS, BA, Veronika Bachanova, MD PhD, Greg M Vercellotti, MD FACP, Todd E. DeFor, MS, Julie Curtsinger, Paul Alexander Robertson, MD, Kevin C Conlon, MD, Thomas A Waldmann, MD, David H. McKenna, MD, Bruce Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 2649.

https://doi.org/10.1182/blood.V130.Suppl_1.2649.2649

Published: 2017

Journal Articles

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Tracy Tiffany Wang, BS, Jun Yang, MD, Yong Zhang, PhD, Meili Zhang, PhD, Kevin C Conlon, MD, Yutaka Tagaya, B.M., PhD, Thomas L Olson, PhD, David J Feith, PhD, Nazli Azimi, Pharm.D., PhD, Thomas A. Waldmann, MD, Thomas P Loughran, Jr., MD

Blood (2017) 130 (Supplement 1): 3585.

https://doi.org/10.1182/blood.V130.Suppl_1.3585.3585

Published: 2017

Journal Articles

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Sigrid Dubois, PhD, Milos D. Miljkovic, MD, Thomas Fleisher, Jennifer Hsu, RN, Thomas A Waldmann, MD, Kevin C Conlon, MD

Blood (2017) 130 (Supplement 1): 3840.

https://doi.org/10.1182/blood.V130.Suppl_1.3840.3840

Published: 2017

Journal Articles

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T-Cell Leukemia/Lymphoma

Blood (2017) 130 (Supplement 1): 731.

https://doi.org/10.1182/blood.V130.Suppl_1.731.731

Published: 2017

Journal Articles

Role of Recipient CD8 + T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells

Robin Williams, MD MS, Sarah Cooley, MD, Veronika Bachanova, MD, Thomas A Waldmann, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD, Michael R. Verneris, MD

Blood (2016) 128 (22): 503.

https://doi.org/10.1182/blood.V128.22.503.503

Published: 2016

Journal Articles

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

Jeffrey S. Miller, MD, Michael R. Verneris, MD, Julie Curtsinger, PhD, Todd E. DeFor, MS, David McKenna, MD, Thomas A Waldmann, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD, Sarah Cooley, MD

Blood (2015) 126 (23): 566.

https://doi.org/10.1182/blood.V126.23.566.566

Published: 2015

Journal Articles

A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation

Masao Nakagawa, MD PhD, Roland Schmitz, PhD, Wenming Xiao, Carolyn K Goldman, Weihong Xu, Yandan Yang, PhD, Thomas A Waldmann, MD, Louis M. Staudt, MD PhD

Blood (2014) 124 (21): 3566.

https://doi.org/10.1182/blood.V124.21.3566.3566

Published: 2014

Journal Articles

Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy

Robert J. Kreitman, MD, Rajat Singh, Maryalice Stetler-Stevenson, MD, PhD, Thomas A. Waldmann, MD, Ira Pastan, MD

Blood (2011) 118 (21): 2575.

https://doi.org/10.1182/blood.V118.21.2575.2575

Published: 2011

Journal Articles

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Blood (2011) 118 (21): 3706.

https://doi.org/10.1182/blood.V118.21.3706.3706

Published: 2011

Journal Articles

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

Deirdre O’Mahony, MD, John E Janik, MD, Jorge A. Carrasquillo, MD, Pamela Seam, MD, Joseph A Fiorillo, MD, Donn Stewart, MD, Chang H Paik, PhD, Suzanne Fioravanti, RN, Millie Whatley, RNMT, Stefania Pittaluga, MD, PhD, Martin W Brechbiel, PhD, John C Morris, MD, Thomas A Waldmann, MD

Blood (2008) 112 (11): 231.

https://doi.org/10.1182/blood.V112.11.231.231

Published: 2008

Journal Articles

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Kamal Sharma, DO, John E. Janik, MD, Deirdre O’Mahony, MD, Donn Stewart, MD, Stefania Pittaluga, MD, Maryalice Stetler-Stevenson, MD, PhD, Elaine S. Jaffe, MD, Mark Raffeld, MD, Thomas A. Fleisher, MD, Cathryn C. Lee, NP, Nicole Urquhart, MD, Seth Steinberg, PhD, Thomas A. Waldmann, MD, John C. Morris, MD

Blood (2008) 112 (11): 2010.

https://doi.org/10.1182/blood.V112.11.2010.2010

Published: 2008

Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Deirdre O’Mahony, MD, John C. Morris, MD, Maryalice Stetler-Stevenson, MD, Helen Matthews, RN, Stefania Pittaluga, MD, Paul Albert, PhD, Karen Kaucic, MD, Luz Hammershaimb, MD, Thomas A. Waldmann, MD, John E. Janik, MD

Blood (2007) 110 (11): 3565.

https://doi.org/10.1182/blood.V110.11.3565.3565

Published: 2007

NARROW

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T-Cell Leukemia/Lymphoma

Role of Recipient CD8 + T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation

Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy

Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only